Table II.
Clinical and MRI characteristics
| ‘Progressive’ N = 45 | ‘Non‐progressive’ N = 44 | Statistics: ‘progressive’ versus ‘non‐progressive’ (P value) | |
|---|---|---|---|
| Age at bs in years, mean (SD) | 39.0 (9.1) | 44.0 (10.3) | 0.01 |
| Male/Female (ratio) | 16/29 (1:1.8) | 9/35 (1:3.8) | 0.13 |
| Disease duration:Time since first symptoms at bs in years, median (IQR) | 8 (6–14) 80 | 10 (8–19) | 0.07 |
| Drug treatmenta (% of patients) | 77 | 0.91 | |
| Scan interval (months), mean, SD, p value | 12.6 (0.7) | 12.6 (1.1) | 0.99 |
| EDSS at bs, median (IQR) | 2.5 (1.5–3.0) | 2.5 (2.0–3.13) | 0.51 |
| EDSS at y1, median (IQR) | 2.5 (1.5–3.5) | 2.5 (2.0–3.13) | 0.26 |
| Statistics: EDSS change, bs versus y1 (P value) | 0.71 | 0.91 | |
| T2 lesion load in ml, median (IQR) at bs | 3.9 (2.4–10.1) | 3.3 (1.3–7.6) | 0.25 |
| T2 lesion load in ml, median (IQR) at y1 | 4.6 (2.6–11.3) | 3.1 (1.1–7.1) | 0.06 |
| T2 lesion volume change, bs versus y1: P‐value | <0.001 | <0.001 | |
| T1 lesion load in ml, median (IQR) at bs | 1.2 (0.3–3.5) | 0.9 (0.2–2.6) | 0.37 |
| T1 lesion load in ml, median (IQR) at y1 | 1.4 (0.5–4.1) | 0.8 (0.2–2.4) | 0.06 |
| T1 lesion volume change, bs versus y1: p‐value | <0.001 | <0.001 | |
| New T2‐Lesions at y1 (count) | 1 (0–4) | 0 (0–0) | |
| New Gd‐enhancing lesions at y1 (count) | 0 (0–1) | 0 (0–0) | 0.014 |
| T1/T2 at bs (mean, SD) | 0.32 (0.19) | 0.29 (0.16) | 0.45 |
| T1/T2 at y1 (mean, SD) | 0.33 (0.18) | 0.27 (0.15) | 0.06 |
| GMV in cm3, (mean SD) at bs | 656 (78) | 637 (74) | 0.42 |
| GMV in cm3, (mean SD) at y1 | 643 (80) | 638 (75) | 0.78 |
| PGMVC, bs versus y1: (mean, SD), | −1.28 (0.3) | 0.17 (0.1)0.59 | |
| P‐value | 0.001 | 0.59 |
a
No changes in medication during follow‐up.
SD, standard deviation; IQR, interquartile range; EDSS, expanded disability status scale; bs, baseline; y1, year1; GMV, global grey matter volume; PGMVC, percentage grey matter volume change.